Silver Book Fact

In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.

Rascol O, Brooks D, Korczyn A, De Deyn P, et al. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa. N Engl J Med. 2000; 342(20): 1484-91. http://content.nejm.org/cgi/content/abstract/342/20/1484

Reference

Title
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa
Publication
N Engl J Med
Publication Date
2000
Authors
Rascol O, Brooks D, Korczyn A, De Deyn P, et al.
Volume & Issue
Volume 342, Issue 20
Pages
1484-91
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Some studies have indicate that the management of high cholesterol, type 2 diabetes, high blood pressure, overweight or obesity, and other cardiovascular risk factors may help avoid or delay cognitive…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…